Latest News

Deep learning-based motion correction with the CLEAR Motion software reportedly bolsters cardiac imaging quality while the PIQE 1024 Deep Learning Reconstruction software offers equivalent SNR to photon-counting CT for high-resolution views of objects less than 0.5 mm.

Researchers said the combination of 18F-flotufolastat PET/MRI may lead to a 57 percent reduction of prostate biopsies in comparison to a 25 percent reduction with prostate MRI alone.

The newly FDA-cleared PACS Viewer from CliniComp reportedly allows direct review and analysis of imaging within a patient’s chart.

In a recent interview, Nina Kottler, MD, offered her perspective on findings from a recent report on AI in health care, AI integration challenges and what the future holds with AI in radiology.

In comparison to everolimus, the peptide receptor radionuclide therapy (177Lu)Lu-edotreotide provided over a nine month longer median progression-free survival for patients with gastroenteropancreatic neuroendocrine tumours (GEP NETs), according to new phase 3 research.

In an amusing take on the subject, this author suggests that having a colleague with dedicated expertise in curtailing unnecessary imaging requests could have an impact in reducing burgeoning worklists.

Catch up on the top radiology content of the past week.

For patients with known or suspected neuroendocrine tumors, the radiopharmaceutical 64Cu-SARTATE offered over 50 percent higher average detection of liver foci than 68Ga-DOTATATE at four hours and 20 hours post-injection, according to research presented at the recent SNMMI conference.

In a recent interview, Amy Patel, MD, discussed recent research on breast cancer screening, pertinent obstacles and keys to facilitating improved adherence with mammography screening.

Emerging research demonstrates that those with total plaque volume > 750 mm3 have an 18.6 percent risk of MACE at four years in comparison to a 1.4 percent MACE risk for those with no plaque.

The Star RF Electrode and VIVA RF Electrode are reportedly the first devices to garner a specific cleared indication for benign thyroid nodule ablation.

In comparison to the 2009 International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer, researchers found that the updated 2023 FIGO system had over a 17 percent decrease for substage agreement between pelvic MRI and pathology findings.

The Mammomat B.brilliant’s ClearCEM image reconstruction technique reportedly utilizes advanced algorithms to facilitate improved noise reduction and lesion enhancement.